Jan. 11, 2024 — The FDA said Thursday that a review of a category of popular diabetes and obesity drugs found no link between the drugs and a rise in suicidal thoughts.
Medications include Ozempic, Wegovy and Mounjaro. The FDA Urges anyone with concerns to talk to their doctor and said there “may be a small risk” as a link has not been completely ruled out.
NBC News noted that the announcement got here after research was published last week showing that folks taking semaglutide, the lively ingredient in Ozempic and Wegovy, had a lower risk of suicidal thoughts than patients taking other obesity and diabetes medications revenue.
European officials had previously said they were investigating unscientific reports that some people taking semaglutide had considered harming themselves.
“FDA’s preliminary evaluation found no evidence that use of these drugs causes suicidal thoughts or actions,” the FDA said Thursday.
The agency is reviewing reports on greater than a dozen drugs approved since 2005, called GLP-1 receptor agonists. These medicines help control blood sugar levels and reduce the chance of heart disease in individuals with type 2 diabetes. Some of those medications are also utilized by obese or obese people to shed some pounds.
The FDA said it could proceed to research the situation.
Patients with concerns mustn’t stop taking their medications without first talking to their doctor, the FDA advised.
Anyone in crisis or distress can call or text 988 or leave https://988lifeline.org/that gives free support 24 hours a day, 7 days per week.